中文  English

李德福

发布时间:2013-03-27 15:25:11  浏览次数:1922652  来源:博鳌亚洲论坛

李德福

李德福,1958年出生。1982年毕业于南开大学历史系,后进入天津市委工作,后任党史研究室编辑出版处处长,1992年创建天津开发区永泰房地产开发有限公司,进入房地产开发业,后成立永泰红磡控股集团有限公司,任董事长,进入21世纪,收购上海上市公司“望春花”,后通过整合,将上市公司更名“中源协和干细胞生物工程股份公司”,专门从事干细胞生命科技产业,是中国唯一的干细胞上市公司,李德福先生同时于2011年创办永泰红磡严老产业集团,投入养老产业各项业务,集团同时涉足股权基金投资业务。李德福先生是天津市政协委员,同时兼任市政协的人口资源与城乡建设委员会副主任,天津工商联副主席,中国养老产业协会常务理事,全国工商联房地产商会副会长。自1992年开始投资以干细胞为主的再生医学产业,被喻为“中国干细胞投资第一人”。近年来作为干细胞为题材的唯一中国上市公司,中源协和干细胞基因工程公司的控股股东,先后投资数亿元人民币,建立起覆盖中国四分之三人口的干细胞采集存储及未来应用的平台,国家级干细胞临床转化基地,也是全世界最大的干细胞储存基地。

Li Defu, born 1958, graduated from the Department of History of Nankai University in 1982. After graduation, he worked in the Tianjin Municipal Party Committee and served as Chief of the Editing and Publication Division of the Party History Research Section. In 1992, he set up the Tianjin Development Area Yongtai Real Estate (Eontime) Development Co., Ltd. and entered the real estate development industry. Later, he funded Yongtai Holding Group Limited and served as Chairman. Entering the 21st century, he acquired the listed company, Shanghai MET. After integration, the company was renamed Zhongyuan Union Stem Cell Bio-Engineering Corporation to specialize in the stem cell life science industry. This is the only listed stem cell company in China. In 2011, Mr. Li Defu founded Yongtai Pension Industry Group and invested in various pension businesses. The Group also operates in equity fund investment businesses. Mr. Li Defu is a member of the Tianjin Municipal Committee of the Chinese People’s Political Consultative Conference and Deputy Director of its Committee of Population, Resources and Urban/Rural Construction, Vice Chairman of the Tianjin Federation of Industry and Commerce, Executive Director of the Chinese Pension Industry Association and Vice President of the Real Estate Chamber of Commerce of All-China Federation of Industry and Commerce. Since 1992, Li Defu has been investing in the stem cell-based regenerative medicine industry and has been hailed as the “No.1 Stem Cell Investor in China”. In recent years, he has, as the controlling shareholder of Zhongyuan Union Stem Cell Bio-Engineering Corporation, China’s only listed stem cell company, successively invested hundreds of millions of yuan, RMB, to set up a stem cell collection, storage and application platform that covers three-quarters of China’s population and to establish the National Stem Cell Clinical Transformation Base, the largest stem cell storage base in the world.